{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T15:37:34Z","timestamp":1649000254343},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T00:00:00Z","timestamp":1140739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical effect. The goals of this phase I study were to determine the maximum-tolerated dose (MTD) of chronomodulated capecitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT), the safety profile of this way of administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with advanced solid tumours who had failed to response to standard therapy or for whom no standard therapy was available were elegible for this study. Capecitabine was administered orally according to following schedule: 1\/4 of dose at 8:00 a.m.; 1\/4 of dose at 6:00 p.m. and 1\/2 of dose at 11:00 p.m. each day for 14 consecutive days, followed by a 7-day rest period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All 27 patients enrolled onto the study were assessable for toxicity. The most common toxicities during the first two cycles of chemotherapy were fatigue, diarrhoea and hand foot syndrome (HFS). Only one out of the nine patients treated at capecitabine dose of 2,750 mg\/m<jats:sup>2<\/jats:sup> met protocol-specified DLT criteria (fatigue grade 4). However, at these doses the majority of cycles of therapy were delivered without dose reduction or delay. No other episodes of DLT were observed at the same dose steps and at the lower dose steps of capecitabine (1,500\/1,750\/2,000\/2,250\/2,500 mg\/m<jats:sup>2<\/jats:sup>). The dose of 2,750 mg\/m<jats:sup>2<\/jats:sup> is recommended for further study. Tumor responses were observed in patients with metastatic breast and colorectal cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>High doses of chronomodulated capecitabine can be administered with acceptable toxicity. The evidence of antitumor activity deserves further investigation in phase II combination chemotherapy studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-6-42","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T19:14:30Z","timestamp":1140808470000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and\/or metastatic cancer"],"prefix":"10.1186","volume":"6","author":[{"given":"Daniele","family":"Santini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"La Cesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Gasparro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,2,24]]},"reference":[{"key":"394_CR1","doi-asserted-by":"crossref","unstructured":"Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal: a randomised trial. Nordic gastrointestinal Tumor adjuvant therapy group. J Clin Oncol. 1992, 10: 904-911.","DOI":"10.1200\/JCO.1992.10.6.904"},{"key":"394_CR2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","volume":"6","author":"HM Pinedo","year":"1988","unstructured":"Pinedo HM, Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988, 6: 1653-1664.","journal-title":"J Clin Oncol"},{"key":"394_CR3","first-page":"105","volume":"19","author":"CH Kohne-Wompner","year":"1992","unstructured":"Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol. 1992, 19: 105-125.","journal-title":"Semin Oncol"},{"key":"394_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","volume":"306","author":"W Scheithauer","year":"1993","unstructured":"Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993, 306: 752-755.","journal-title":"BMJ"},{"key":"394_CR5","doi-asserted-by":"crossref","unstructured":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992, 10: 896-903.","DOI":"10.1200\/JCO.1992.10.6.896"},{"key":"394_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998, 352: 1413-1418. 10.1016\/S0140-6736(98)02309-5.","journal-title":"Lancet"},{"key":"394_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355: 1041-1047. 10.1016\/S0140-6736(00)02034-1.","journal-title":"Lancet"},{"key":"394_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343: 905-914. 10.1056\/NEJM200009283431302.","journal-title":"N Engl J Med"},{"key":"394_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1040-8428(00)00070-6","volume":"35","author":"JL Misset","year":"2000","unstructured":"Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E: Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol. 2000, 35: 75-93.","journal-title":"Crit Rev Oncol Hematol"},{"key":"394_CR10","first-page":"4","volume":"25","author":"E Raymond","year":"1998","unstructured":"Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998, 25: 4-12.","journal-title":"Semin Oncol"},{"key":"394_CR11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18: 2938-2947.","journal-title":"J Clin Oncol"},{"key":"394_CR12","first-page":"252","volume":"22","author":"RM Goldberg","year":"2003","unstructured":"Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP: N9741: oxaliplatin [oxal] or CPT-11 + 5-fluorouracil [5-FU]\/leucovorin [LV] or oxal + CPT-11 in advanced colorectal cancer. Updated efficacy and quality of life [QOL] data from an intergroup study. Proc ASCO. 2003, 22: 252-","journal-title":"Proc ASCO"},{"key":"394_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdf065","volume":"13","author":"E Diaz-Rubio","year":"2002","unstructured":"Diaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J: Capecitabine [Xeloda] in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol. 2002, 13: 558-565. 10.1093\/annonc\/mdf065.","journal-title":"Ann Oncol"},{"key":"394_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001, 40: 85-104. 10.2165\/00003088-200140020-00002.","journal-title":"Clin Pharmacokinet"},{"key":"394_CR15","first-page":"407","volume":"36","author":"H Ishitsuka","year":"1995","unstructured":"Ishitsuka H, Miwa M, Ishikawa : Capecitabine: an orally available fluoropyrimidine with tumour selective activity. Proc Am Assoc Cancer Res. 1995, 36: 407-[abstr 2426]","journal-title":"Proc Am Assoc Cancer Res"},{"key":"394_CR16","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorinas first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001, 19: 2282-2292.","journal-title":"J Clin Oncol"},{"key":"394_CR17","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","volume":"16","author":"M Mackean","year":"1998","unstructured":"Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer. J Clin Oncol. 1998, 16: 2977-2985.","journal-title":"J Clin Oncol"},{"key":"394_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000087285","volume":"69","author":"D Santini","year":"2005","unstructured":"Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L, Tonini G: Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-FU and irinotecan resistant advanced colorectal cancer patients. Oncology. 2005, 69: 27-34. 10.1159\/000087285.","journal-title":"Oncology"},{"key":"394_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00001622-199607000-00012","volume":"8","author":"F Levi","year":"1996","unstructured":"Levi F: hronotherapy for gastrointestinal cancers. Curr Opin Oncol. 1996, 8: 334-41.","journal-title":"Curr Opin Oncol"},{"key":"394_CR20","first-page":"17","volume":"38:18","author":"P Therasse","year":"2002","unstructured":"Therasse P: Measuring the clinical response: What does it mean?. Eur J Cancer. 2002, 38:18: 17-23.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-6-42\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-42","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:40:17Z","timestamp":1630449617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-6-42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-6-42","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,24]]},"assertion":[{"value":"23 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"42"}}